CSPC Pharmaceutical and AstraZeneca Strike Third AI-Driven Drug Discovery Deal, Bringing Total Collaboration Value to $25.6 Billion

CSPC Joins Hands with AstraZeneca Again!

7Month2Day,CSPCAnnouncement: The Company Has Entered Into an Agreement withAstraZenecaSigned an AI drug discovery collaboration.

The two parties will establish a long-term strategic R&D collaboration focused on siRNA oligonucleotide therapeutics.

The announcement shows that CSPC will rely on its proprietaryAI-driven molecular design models and fully automated high-throughput screening systems enable the efficient identification of nucleic acid drug molecules with high activity and enhanced extrahepatic targeting potential.

According to statistics from Zhiyaoju, this marks CSPC’s recent one-year [collaboration/interaction] with AstraZenecawithCSPCthe third timeAIPlatform collaboration, with a cumulative amount reaching up to $25.6 billion.

Three Collaborations with AstraZeneca

Today, AstraZeneca and CSPC have formed a deep strategic partnership.

2025Year6month, the two parties reached an agreement with a total amount of up to53.3$100 millioncooperation agreement, leveraging CSPC'sAIDriving an efficient drug discovery platform to jointly discover and develop novel oral small-molecule drug candidates.

Pursuant to the terms of this Agreement,Advance Payment Reached12hundred million USD, with the maximum potential total transaction value reaching up to185hundred million U.S. dollars.

Through three collaborations, the cumulative transaction value between CSPC and AstraZeneca has fully demonstrated itsAIDrug Development Platform'sTechnical Strength Has Been Recognized by Top Global Pharmaceutical Companies。

In recent years, asEstablished Pharmaceutical Company Originating from Generic Drugs，CSPCIncreased efforts inAIPlatform investment accelerates the transition to innovative drugs.

Currently, CSPCEstablished a framework based onAIAI-Driven High-Efficiency Drug Discovery Platform.

The platform leveragesAIAnalyze the binding modes of target proteins with compounds and perform targeted optimization to significantly enhance the screening efficiency and success rate of candidate molecules.。

Currently, theCandidate Drugs Generated by the PlatformYS2302018(Lipoprotein (a) inhibitor) andSYH2039（GLP-1receptor agonists) have been licensed to AstraZeneca and BeOne, respectively.

This not only demonstrates the platform's technological maturity but also generates substantial licensing revenue for the company.。

andTo address the issue ofAIThe bottleneck in the intermediate link from molecular design to experimental validation, CSPC2025Invested annually in the construction of fully automatedAILaboratory.

The company stated,The introduction of automated equipment, such as robotic arms, has enabled unmanned operation in the synthesis of small-molecule compounds.

Experimental data show that,AITechnology Shortens the Time for Early Discovery of New Drugs30%, R&D costs were reduced by nearly50%, and improved the accuracy of compound screening3more than times。

This collaboration with AstraZeneca is also built on delivery technologies and peptide drugsAIOn the discovery platform.

The design space for peptide molecules is vast, and the cost of traditional trial-and-error approaches is extremely high.AdditionallyOn the one hand, its druggability, safety, and delivery methods are highly complex, making it difficult to systematically optimize based on single empirical experience.

andAIAble toIn the vast combinatorial space,Rapid Design and Screening of Candidate Molecules for Drug Targets，and can be systematically optimized in terms of efficacy, selectivity, and signaling bias.

Traditional pharmaceutical companies are collectivelyTurnAI

From the Perspective of the Global Pharmaceutical Industry,AI The role in drug development has evolved.

In the past,AIMore often regarded as a tool,NowadaysAIGradually Becoming an EnterpriseInfrastructure for Scalable Innovation.

It is not only CSPC; multiple established pharmaceutical companies have begun to collectively bet on AI platforms to accelerate R&D speed.

For example,Harbour BioMedAnnouncing the world’s first fully human heavy-chain antibody (HCAb) Large Model, and will alsoBuild aAIDriver, End-to-End AutomationIdea-to-ClinicalPlatform,Accelerate the R&D of antibody drugs.

Fosun PharmathenInvested substantial resources in R&D to introduce a-basedChatGPTHigh EfficiencyAIToolsPharmAID, creating a smarter and more efficient work environment, while also engaging in deep collaboration with Insilico Medicine and othersAIR&D Enterprise.

BeOneAs the only pharmaceutical company in China to have established a functional genomics platform, it has integratedCRISPRScreening andAITarget Prediction Technology for the Development of Gene Editing Therapies。

PharmaronthenCompleteHaiXin ZhiHui's Holding，Obtain High QualityPatient Data andAITechnology Platform: Expanding and Accelerating the Digital and Intelligent Upgrade of Pharmaron’s Innovative Drug R&D Service Capabilities and Systems。

Recommended Reading